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Abstract
Background: Cell migration is essential for development and tissue repair, but it also contributes to disease. Rho
GTPases regulate cell migration, but a comprehensive analysis of how each Rho signalling component affects
migration has not been carried out.
Results: Through an RNA interference screen, and using a prostate cancer cell line, we find that approximately 25%
of Rho network components alter migration. Some genes enhance migration while others decrease basal and/or
hepatocyte growth factor-stimulated migration. Surprisingly, we identify RhoH as a screen hit. RhoH expression is
normally restricted to haematopoietic cells, but we find it is expressed in multiple epithelial cancer cell lines. High
RhoH expression in samples from prostate cancer patients correlates with earlier relapse. RhoH depletion reduces
cell speed and persistence and decreases migratory polarity. Rac1 activity normally localizes to the front of
migrating cells at areas of dynamic membrane movement, but in RhoH-depleted cells active Rac1 is localised
around the whole cell periphery and associated with membrane regions that are not extending or retracting. RhoH
interacts with Rac1 and with several p21-activated kinases (PAKs), which are Rac effectors. Similar to RhoH
depletion, PAK2 depletion increases cell spread area and reduces cell migration. In addition, RhoH depletion
reduces lamellipodium extension induced by PAK2 overexpression.
Conclusions: We describe a novel role for RhoH in prostate cancer cell migration. We propose that RhoH promotes
cell migration by coupling Rac1 activity and PAK2 to membrane protrusion. Our results also suggest that RhoH
expression levels correlate with prostate cancer progression.
Background
Cell migration is essential for the development of multi-
cellular animals, as well as for immune responses and
wound healing. Cell migration also contributes to the
development of several human diseases, including
cancer, heart disease and chronic inflammatory disorders
[1–3]. Many cell-surface receptors and intracellular sig-
nalling proteins contribute to cell migration, and inhibi-
tors of some of these molecules are being developed for
the treatment of human diseases [4, 5].
Rho GTPases are intracellular coordinators of cell mi-
gration signalling. Most Rho GTPases cycle between an
active GTP-bound and an inactive GDP-bound form.
They are activated by guanine nucleotide exchange fac-
tors (GEFs), which stimulate exchange of GDP for GTP,
and inactivated by GTPase-activating proteins (GAPs),
which stimulate their intrinsic GTPase activity, hydrolys-
ing GTP to GDP [6]. Most Rho family members are
post-translationally modified at the C-terminus by
addition of lipid groups, which facilitate their interaction
with membranes. Some Rho GTPases are regulated by
guanine nucleotide dissociation inhibitors (GDIs), which
extract them from membranes by binding to the lipid
group as well as other regions of the protein [7]. When
bound to GTP, Rho GTPases interact with a wide range
of downstream effectors to induce signalling, including
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enzymes, adaptor proteins and regulators of actin poly-
merisation. Several Rho family members are atypical:
They have amino acid substitutions that prevent GTP
hydrolysis and are thus constitutively bound to GTP.
These include RhoH and Rnd proteins [8, 9]. The activ-
ity of these proteins can be regulated by post-
translational modifications; for example, Rnd proteins
are inhibited by serine/threonine phosphorylation and
subsequent binding to 14-3-3 proteins [10], and RhoH
can be tyrosine phosphorylated by Src family kinases,
which promotes its interaction with ZAP70 in T cells or
Syk in mast cells [11–13].
Several groups have used RNA interference (RNAi)
screens to identify regulators of cell morphology and/or
cell migration. Targeted screens of cytoskeletal regula-
tors as well as whole genome screens have identified
new genes involved in cell migration [14–18].
Here we have carried out a focussed RNAi screen to
identify which Rho GTPases and their interacting part-
ners regulate cancer cell migration. Unexpectedly, we
identified RhoH as a key regulator of cancer cell migra-
tion. RhoH is widely assumed to be expressed only in
haematopoietic cells based on analysis of mouse tissues
[19]. We show here that RhoH is in fact expressed in a
wide range of prostate and breast cancer cell lines and
human cancers. We demonstrate that RhoH stimulates
cell migration by promoting Rac1- and PAK-driven
membrane protrusion.
Results
An RNAi screen of the Rho network identifies groups of
genes with different effects on cancer cell migration
To investigate which Rho GTPase network components
affect cell migration, we used a small interfering RNA
(siRNA) library containing pools of four siRNAs target-
ing each of 202 genes encoding Rho GTPases, RhoGEFs,
RhoGAPs and Rho targets, together with four control
siRNA pools (Additional file 1: Table S1). The screen
method used a modified wound healing assay to study
migration (see Methods) with PC3 prostate cancer cells
(Fig. 1a). PC3 cells express N-cadherin but not E-
cadherin and only make transient cell-cell interactions.
They predominantly migrate as single cells and thus
resemble cells that have undergone epithelial-to-
mesenchymal transition [20, 21].
The assay conditions were established using siRNAs tar-
geting Cdc42 and control siRNA. Migration was evaluated
by image analysis comparing the area covered with cells at
different times after creation of the ‘wound’. Cells were
stained with the fluorescent dye carboxyfluorescein succi-
nimidyl ester (CFSE) to allow rapid quantification of rela-
tive cell number in the wound area. Images were treated
with a flatten background filter and then thresholded so
that differences in CFSE uptake between individual cells
did not affect the results (Fig. 1b, see Methods). After 24
h, control siRNA-transfected cells covered approximately
50–60% of the wound area (Fig. 1b). This was established
as the optimal time point for the screening, because it
allowed the identification of genes that inhibited and
enhanced migration.
Cdc42 depletion strongly reduced cell migration
(Fig. 1b, c). We compared migration on uncoated
plastic with that on Matrigel-coated plastic (Fig. 1c).
Although cells migrated faster on Matrigel, the effect
of Cdc42 depletion was still clear on uncoated plastic,
and this condition was more reproducible for
screening than Matrigel coating (unpublished data).
Migration was analysed in the presence and absence
of hepatocyte growth factor (HGF) (Fig. 1a), which
promotes migration and invasion of many cell types
[22] and stimulated PC3 cell migration in this assay
(Fig. 1c). The siRNA for Cdc42 as well as an siRNA
for RhoA showed reliable depletion of proteins under
the assay conditions (Fig. 1d).
The siRNA library screen was repeated three times. To
identify if any siRNA pools affected cell viability, PC3
cells were plated onto 96-well plates 24 h after transfec-
tion, and the fluorescence was measured after 24 and 48
h to monitor cell viability (Fig. 1a). Only a few siRNA
pools affected cell number in each round of the screen.
Those wells that had significantly fewer cells than the
mean in an individual screen and/or did not form a
defined wound area were excluded from the migration
analysis. Only PLD5, CYBB, PLXNB1 and PLXNB2
siRNA pools affected viability in all three independent
screens (Additional file 1: Table S1; Z-score < −1.0).
Screen results were analysed by calculating the migra-
tion rate for each individual siRNA pool compared to the
mean of all the wells in the screen (Fig. 2a). A Z-score of
+/−1.0 was used as the cutoff for significance in each
screen. Analysis of the results showed that 51 of the 202
siRNA pools tested significantly affected cell migration in
the three screens, which included GEFs, GAPs, effectors
and Rho GTPases (Table 1; Additional file 1: Table S1). Of
these, 21 siRNA pools inhibited basal cell migration,
whereas 20 siRNA pools increased basal cell migration
(Fig. 2b, c). Ten siRNA pools only affected HGF-
stimulated migration but not basal migration (Table 1).
It is interesting that siRNA pools for 6 of the 20
(30%) Rho GTPase family members altered cell migra-
tion (Fig. 2a). All 20 Rho GTPases are expressed in
PC3 cells at the messenger RNA (mRNA) level [23].
We previously showed that siRNA pools for 8 of 20
Rho GTPases affect PC3 cell adhesion to endothelial
cells [23]. Also included in the library were siRNAs
targeting RhoBTB3, Miro1 and Miro2, which are not
classified as Rho GTPases [24] (Additional file 1:
Table S1). RhoBTB3 siRNAs impaired migration only
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when cells were stimulated with HGF. RhoBTB3 is
associated with the Golgi and regulates protein stabil-
ity through the proteasome [25, 26].
In total, siRNA pools for 20 RhoGEFs affected cell mi-
gration, of the 70 included in the library (29%). All of the
9 RhoGEF siRNA pools that reduced basal cell migration
are reported to be GEFs for Rac and/or Cdc42, consistent
with roles of Rac and Cdc42 in lamellipodium-driven mi-
gration [27]. For RhoGAPs, 10 of 44 (23%) siRNA pools
included in the library had a phenotype. Interestingly, a
larger number of RhoGAP siRNA pools enhanced cell
migration than decreased migration either in the presence
or absence of HGF (Table 1).
Of the 57 Rho effectors in our library, 15 are hits
(26%) (Table 1). Some of these also regulate Rho
GTPases, such as Smurf1, an ubiquitin ligase for mul-
tiple proteins including RhoA [28], for which the siRNA
pool inhibited migration. None of the three RhoGDIs
had a phenotype in PC3 cells.
siRNA pools targeting some highly homologous GEFs
and GAPs had opposite effects on migration, indicating
that despite their similar domain structure they are likely
c
a b
d
Fig. 1 Design and validation of siRNA screen. a Schematic representation of the screen design and implementation. PC3 cells were stained with
carboxyfluorescein succinimidyl ester (CFSE) and reverse transfected with siRNAs. Cells were then divided and seeded into one 96-well plate to
carry out cell viability analysis and two separate 96-well plates to measure migration by Oris™ assay with and without hepatocyte growth factor
(HGF) (Table 1). Hits from the screen were quantified. b Conditions for the migration screen were tested using an siRNA targeting Cdc42 (siCdc42-
2, Additional file 1: Table S1) and control siRNA. Images show examples of CFSE-labelled PC3 cells immediately after removal of the Oris™ stopper
(0 h) and 24 h later. Bottom images are thresholded 24 h images (see Methods). White dotted circle indicates wound area at 0 h. c. Quantification
of the effect of Cdc42 depletion on migration in the Oris™ assay using the screen conditions, comparing cells on uncoated plastic and Matrigel-
coated plastic. n = 3, mean +/− standard error of the mean (SEM); **p ≤ 0.01, *p ≤ 0.05, Student’s t test. d Single siRNAs targeting Cdc42
(siCdc42-2), RhoA (siRhoA-1) or control siRNA were tested for knockdown of protein expression using the screen conditions. Cells were lysed 72 h
after transfection, and cell lysates western blotted with antibodies to Cdc42 and RhoA, and α-tubulin as a loading control
Tajadura-Ortega et al. BMC Biology  (2018) 16:29 Page 3 of 20
to have different functions. These include the RhoGEFs
FGD2 and FGD4 and the RhoGAPs ARAP1, ARAP2 and
ARAP3 (Table 1). Interestingly, ARAP1/2/3 are RhoGAPs
with different specificities for RhoA, Cdc42 and Rac1,
which also have ArfGAP and Ras-interacting domains, in-
dicating the importance of these proteins in integrating in-
formation from different signalling pathways [29].
Since the siRNA screen was carried out with pools of
four siRNAs per gene, we investigated whether the phe-
notypes were reproducible with individual siRNAs. We
chose to focus on the six Rho GTPases that scored as
hits: RhoC, RhoH and RhoV siRNA pools decreased mi-
gration, whereas Rac3, RhoQ and RhoBTB1 pools in-
creased migration (Table 1). Using two different siRNAs
from the pool for each gene, we confirmed that RhoC
depletion decreased migration, as previously observed
[30]. Rac3, RhoQ and RhoBTB1 depletion reproducibly
increased migration (Fig. 2d), in line with the results of
the screen. Results for RhoH are reported below. Sur-
prisingly, two RhoV siRNAs individually increased
a
b
c
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Fig. 2 Screen of Rho RNAi library identifies four cell migration phenotypes. The migration screen was performed with PC3 cells transfected with
siRNA pools or single siRNAs targeting the indicated genes. After 24 h, cells were seeded at confluence into 96-well plates containing Oris™
stoppers. After 24 h, the stoppers were removed and cells were treated with or without 10 ng/ml HGF for 24 h. Images of cells were acquired
immediately after removing the stoppers (0 h) and 24 h later. a Graph shows migration Z-scores (see Methods) for the GTPases included in the
screen in normal medium (top panel) or medium containing HGF (bottom panel); n = 3. b Representative images of migration area (24 h after
stopper removal) for representative hits from each phenotypic category: no effect on migration (siControl), accelerated migration (RhoQ, Rac3),
impaired migration (RhoC, RhoV), impaired migration only in response to HGF (RhoBTB3). White dotted circle indicates wound area at 0 h. c Pie
charts show number of genes giving each phenotype, based on type of gene (Rho GTPase, RhoGEF, RhoGAP, Rho effector). Note that BCR, which
contains both a RhoGEF and a RhoGAP domain, was included as a GAP in the pie chart for accelerated migration and indicated with an asterisk.
d Migration for cells transfected with the indicated single siRNAs is shown as percentage of control siRNA-transfected cells +/− SEM, n = 3; *p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001, Student’s t test
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migration (Fig. 2d), but another single siRNA (siRhoV-4)
reduced migration (data not shown), suggesting that this
one might have dominated the pool as an off-target.
RhoH regulates PC3 cell migration
Of the hits from our screen, we chose to analyse the ef-
fect of RhoH on cell migration in more detail, because it
was an unexpected hit: RhoH is considered to be
expressed only in haematopoietic cells and has previ-
ously only been studied in haematopoietic cells [19]. The
RhoH gene is present in vertebrates but is not found in
other clades [24]; thus it is not present and therefore
would not be identified in migration/morphology
screens in model organisms such as Drosophila melano-
gaster or Caenorhabditis elegans.
To confirm the effect of RhoH depletion on PC3 cell mi-
gration, we tested cells transfected with the pool of RhoH
siRNA oligos on both uncoated plastic and Matrigel-coated
plastic. RhoH depletion reduced cell migration on both
substrata in the modified scratch wound assay (Fig. 3a).
Three of the four individual siRNA oligos in the pool also
reduced migration (Fig. 3b), and all four down-regulated
RhoH mRNA expression in PC3 cells (Fig. 3c). We were
not able to detect endogenous RhoH protein with commer-
cially available RhoH antibodies, although one antibody did
detect exogenously expressed RhoH (Fig. 3d). The four
individual siRNAs in the RhoH pool all knocked down
exogenously expressed RhoH protein.
In addition to the modified scratch wound assay,
RhoH depletion reduced PC3 cell chemotaxis through
transwells towards a gradient of fetal calf serum
(FCS) (Fig. 3e). Together these results indicate that
RhoH is required for optimal migration and chemo-
taxis of PC3 cells.
Table 1 List of migration hits from siRNA library screen
Impaired migration Accelerated migration HGF-dependent migration
Gene name Accession number Z-score Gene name Accession number Z-score Gene name Accession number Z-score
GTPases RHOC NM_175744 −1.2576 RAC3 NM_005052 1.6714
RHOH NM_004310 −1.1161 RHOBTB1 NM_014836 1.2813
RHOV NM_133639 −1.1100 RHOQ NM_012249 1.1527
RhoGAPs ARAP1 NM_015242 −1.3971 DLC1 NM_006094 1.2716 ARAP3b NM_022481 1.3769
SRGAP3 NM_014850 −1.3048 ARAP2 NM_015230 1.2509 ARHGAP24b NM_031305 1.1005
ARHGAP35 NM_024342 1.1569 SRGAP1b NM_020762 1.0760
ARHGAP4 NM_001666 1.0155
RhoGEFs DOCK5 NM_024940 −2.3762 VAV1 NM_005428 1.6012 ARHGEF4a NM_015320 −1.6365
DOCK11 NM_144658 −1.7138 ARHGEF10 NM_014629 1.1390 ARHGEF19a NM_153213 −1.5797
DOCK6 NM_020812 −1.5419 PLEKHG6 NM_018173 1.1295 ARHGEF14a NM_024979 −1.2354
FGD2 NM_173558 −1.4725 ALS2 NM_020919 1.1294 FGD4b NM_139241 1.1248
DOCK3 NM_004947 −1.3736 PREX2 NM_024870 1.0269
ITSN2 NM_006277 −1.2293 RASGRF1 NM_002891 1.0074
SOS1 NM_005633 −1.1864
DOCK2 NM_004946 −1.1098
FGD5 NM_152536 −1.0918
Effectors NOXA1 NM_006647 −1.4477 RHPN1 NM_052924 1.5692 CITa NM_007174 −1.0435
PIK3R2 NM_005027 −1.3197 TWF1 NM_002822 1.3241 CDC42EPb NM_007061 1.4898
CDC42EP2 NM_006779 −1.2882 PAK4 NM_005884 1.2268
PKN3 NM_013355 −1.2045 PIK3R1 NM_181504 1.1572
PAK7 NM_020341 −1.0864 MLK4 NM_032435 1.0711
SMURF1 NM_020429 −1.0663 PLXNB1 NM_002673 1.0377
PAK2 NM_002577 −1.0318
Other BCR NM_004327 1.1558 RHOBTB3a NM_014899 −0.9751
Hits are divided into Rho GTPases, RhoGEFs, RhoGAPs and effectors and subdivided into siRNA pools that impair or accelerate PC3 cell migration or affect only
HGF-dependent migration; migration Z-score is indicated relative to the mean migration of all genes included in the screen. Accession number: RefSeq accession
number is indicated
HGF hepatocyte growth factor
aHGF-impaired
bHGF-accelerated
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RhoH is expressed in a subset of epithelial cancer cell
lines and in prostate cancer
Given that RhoH is expressed in PC3 cells, we investi-
gated whether other cancer cell lines used in our labora-
tory also expressed RhoH. RNA analysis by polymerase
chain reaction (PCR) detected RhoH expression in PC3
cells and MCF7 breast cancer cells but not DU145 pros-
tate cancer cells or MDA-MB-231 breast cancer cells
(Fig. 4a). All four cell lines expressed RhoA and, interest-
ingly, all lines except MCF7 cells expressed Rac2, which
is also considered to be a haematopoietic cell-specific
gene [19].
To find out whether RhoH is expressed in other epi-
thelial cancer cell lines, we analysed mRNA expression
data in the Cancer Cell Lines Encyclopedia (CCLE) data-
base (http://www.broadinstitute.org/ccle). As expected,
the highest RhoH expression levels were found in T- and
B-cell-derived cancers including lymphoma and
leukemia cell lines. RhoH was also expressed in a variety
of epithelial cancer cell lines, including prostate, breast,
colorectal and lung. The 8 prostate cancer cell lines and
58 breast cancer cell lines in the CCLE database
expressed RhoH mRNA at a wide range of levels. Based
on this analysis, we tested for RhoH expression in a se-
lection of cancer cell lines, including those with high
and low expression based on our CCLE analysis. Quanti-
tative real-time PCR (qPCR) analysis showed that, of the
cancer cell lines analysed, RhoH mRNA levels were high-
est in T47D breast cancer cells followed by LNCaP and
PC3 prostate cancer cells, whereas RhoH mRNA was
very low or not detected in a variety of other cancer cell
lines (Fig. 4b).
We investigated the relevance of RhoH expression in
prostate cancer by analysing existing gene expression
data associated with clinical parameters of disease pro-
gression. Analysis of data from a cohort of patients with
prostate cancer from the Memorial Sloan Kettering
Cancer Center (MSKCC) [31] showed that high levels of
RhoH in the tumour samples correlate with decreased
recurrence-free survival (RFS) (determined by measuring
a b
c d e
Fig. 3 RhoH depletion reduces cell migration. a RhoH depletion reduces migration on uncoated plastic or Matrigel-coated plastic. PC3 cells were
transfected with a control siRNA pool or the pool of four siRNAs targeting RhoH. After 24 h, cells were seeded around Oris™ stoppers. After 24 h,
stoppers were removed and migration was determined 24 h later. Left, example images of cells 24 h after removal of stoppers. White dotted circle
indicates wound area at 0 h. Right, graph showing migration as % of siControl +/− SEM, n = 3; **p ≤ 0.01, Student’s t test. b Individual siRNAs
targeting RhoH reduce migration. PC3 cells were transfected with indicated siRNAs. Cell migration was determined as in a. Graph shows
migration as % of siControl +/− SEM, n = 3; **p ≤ 0.01, ***p ≤ 0.001, Student’s t test. c Relative mRNA expression levels following RhoH
knockdown, compared to control siRNA-transfected cells. Levels were measured by quantitative real-time PCR (qPCR). n = 3; **p ≤ 0.01, ***p ≤
0.001, Student’s t test. d Rho siRNAs reduce expression of exogenous RhoH. PC3 cells were transfected with the indicated siRNAs. Cells were
transfected with human astrocyte (HA)-RhoH 48 h after siRNA transfection. After 24 h, cell lysates were analysed by western blotting with an anti-
RhoH antibody. α-tubulin was used as a loading control. e RhoH depletion reduces migration through transwells. PC3 cells were transfected with
the indicated siRNAs. Cell migration was determined through transwells with 1% fetal calf serum (FCS) as chemoattractant, and migration index
calculated relative to siControl-transfected cells +/− SEM, n = 3; ***p ≤ 0.001, Student’s t test
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prostate-specific antigen (PSA) levels) (Fig. 4c). This
indicates that increased RhoH levels may be associated
with poor prognosis in patients with prostate cancer.
RhoH depletion reduces migration speed and alters
migratory behaviour
We next investigated whether RhoH depletion
affected random migration of subconfluent cells.
Two siRNA oligos were chosen for further studies,
siRhoH-1 and siRhoH-2, because they gave the
strongest knockdown of RhoH mRNA and exogen-
ously expressed RhoH protein (Fig. 3c, d). These two
siRNAs reduced the random migration speed of sin-
gle PC3 cells both with and without HGF addition
(Fig. 5a–c; Additional file 2: Movie S1, Additional
file 3: Movie S2 and Additional file 4: Movie S3).
Detailed analysis of the cell migration tracks (see
Methods) showed that control PC3 cells adopted one of
two migration states during random migration (Fig. 5d, e).
In State 1, the control cells had a slower migration speed
and lower directional persistence (as indicated by a higher
directional variance), whereas in State 2, cells had a higher
migration speed and higher persistence. Following RhoH
depletion, we could still identify two migration states, but
with distinct properties to those of the control cells: In
State 1, cells did not migrate significantly, whereas in State
2, cells had low migration speed and low persistence (high
directional variance), similar to State 1 of the control cells
(Fig. 5d, e). These results indicate that RhoH is important
for both migration speed and directional persistence of
cell movement.
RhoH affects cell shape and actin distribution
To investigate how RhoH affects cell migration, we ana-
lysed the effect of RhoH knockdown on cell shape and
polarity. RhoH depletion with both siRNAs increased
cell spread area and reduced elongation in PC3 cells
(Fig. 6a–d), both of which correlate with a loss of migra-
tory polarity [30]. It also increased the number of mem-
brane protrusions around the cell periphery (Fig. 6e),
consistent with reduced migratory polarity. Similar to
PC3 cells, RhoH depletion increased spread area in two
a
c
b
Fig. 4 RhoH is expressed in a subset of cancer cell lines and correlates with poor prognosis in prostate cancers. a, b Several epithelial cancer cell
lines express RhoH. a RNA was analysed by reverse transcription (RT)-PCR to determine which cell types express mRNA for RhoH, RhoA and Rac2.
GAPDH was used as a control. Gel is representative of three experiments. b RNA was analysed by qPCR for RhoH and Rac1 expression and
normalised to GADPH mRNA. mRNA levels for each cell type are shown relative to levels in PC3 cells. Mean +/− standard deviation for the values
of three technical replicates. c Expression of RhoH in prostate cancer correlates with poor prognosis. Publicly available RNA expression data from
140 prostate cancers from the Memorial Sloan Kettering Cancer Center (GSE21032) were analysed for RhoH expression. Samples were divided into
those with high or low RhoH expression (see Methods). Kaplan-Meier curves show recurrence-free survival (RFS) measured by prostate-specific
antigen (PSA) levels, indicating that high RhoH expression correlates with shorter RFS. Numbers under the graph show the number of patients
without a recurrence event at a given time point, indicating that high RhoH expression correlates with earlier relapse and shorter time to relapse
Tajadura-Ortega et al. BMC Biology  (2018) 16:29 Page 7 of 20
other cell lines that express RhoH: T47D breast cancer
cells (Fig. 6f ) and LNCaP prostate cancer cells (unpub-
lished data). Expression of siRhoH-1-resistant GFP-
RhoH (GFP-RhoH-R1) rescued the increased spread area
of siRhoH-1-transfected cells (Fig. 7a, b), indicating that
the effect is specifically due to RhoH depletion. We con-
clude that RhoH-depleted cells have a reduced ability to
assume a migratory polarity and hence have decreased
migration speed.
Interestingly, RhoH depletion increased the proportion
of binucleated cells in PC3 cells (Fig. 6a, g) as well as in
T47D and LNCaP cells (unpublished data), indicating
that RhoH depletion might inhibit cytokinesis [32]. This
could be a consequence of the increased spread area of
a
b
d e
c
Fig. 5 RhoH depletion alters migration behaviour of PC3 cells. RhoH depletion reduces cell migration speed. PC3 cells were transfected with the
indicated siRNAs targeting RhoH or control siRNA. Cells were seeded in 24-well dishes 48 h after transfection and monitored by time-lapse
microscopy for 24 h. a Example cell tracks are shown for each condition, plotted with their starting point at the intersection of the x- and y-axes.
b Quantification of PC3 cell migration speed. At least 50 cells were tracked from three independent experiments. Boxes of box and whisker plots
show median, 25th and 75th percentiles; whiskers show minimum and maximum values; ***p ≤ 0.001, Student’s t test. c Effect of RhoH on HGF-
induced migration. 48 h after siRNA transfection, cells were transferred to 0.1% FCS with or without 20 ng/ml HGF. Cells were monitored by time-
lapse microscopy for 24 h, with an image taken every 4 min. At least 100 cells were tracked from three independent experiments. Boxes of box
and whisker plots show median, 25th and 75th percentiles; whiskers show minimum and maximum values; **p ≤ 0.01, ***p ≤ 0.001, Student’s t
test. d Data for State 1 and State 2, showing mean migration speed, directional variance (over a time period of 8 min) and proportion of total
time spent in State 1 across all cells (α). e Analysis of cell tracks indicated two modes of migration, State 1 and State 2, with different migration
speeds and persistence (directional variance)
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Fig. 6 RhoH affects cell shape in PC3 cells. Analysis of cell shape. PC3 cells were transfected with the indicated siRNAs targeting RhoH or control
siRNA. After 48 h, cells were seeded on Matrigel-coated glass coverslips. 72 h after transfection, cells were fixed and stained for F-actin (Alexa Fluor
546 phalloidin), tubulin (fluorescein isothiocyanate (FITC)-labelled anti-tubulin antibody) and DNA (4′,6-diamidino-2-phenylindole (DAPI)). a
Representative images of cells. Scale bar 10 μm. Arrows indicate examples of binucleated cells. b–d PC3 cell area, shape factor and elongation
factor were measured using ImageJ from F-actin-stained images. Scatter dot plots show mean +/− SEM; at least 60 cells per condition were
analysed from three independent experiments, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, Student’s t test. e Quantification of the number of extended
protrusions during cell migration. Panels show representative images of siControl- or siRhoH-transfected cells. Arrows indicate protrusions on
migrating cells. Graph shows the average number of protrusions per cell relative to control ***p ≤ 0.001. f T47D cells were transfected with the
indicated siRNAs. After 72 h, cells were fixed and stained for F-actin (Alexa Fluor 546 phalloidin) and DNA (DAPI). Cell area was measured using
ImageJ from F-actin-stained images. Scatter dot plots show mean +/− SEM; n = 3, **p ≤ 0.01, ***p ≤ 0.001, Student’s t test. Relative RhoH mRNA
levels in T47D cells were determined by qPCR using GAPDH as control. Mean +/− SEM, n = 3, ***p ≤ 0.001, Student’s t test. g RhoH depletion
leads to an increase in binucleated cells. Cells were fixed 72 h after siRNA transfection and stained for F-actin (Alexa Fluor 546 phalloidin) and
DNA (DAPI). The % of cells with two or more nuclei were scored; at least 250 cells per condition were analysed from five independent experiments.
Graphs show mean +/− SEM, n = 5, *p ≤ 0.05, ***p ≤ 0.001, Student’s t test. h RhoH depletion reduces cell number. PC3 cell numbers were counted
96 h after siRNA transfection. Graphs show mean +/− SEM, n = 3, *p ≤ 0.05, **p ≤ 0.01, Student’s t test
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ab
Fig. 7 GFP-RhoH rescues the morphological phenotype of RhoH-depleted cells. a Representative images of PC3 cells transfected with GFP, GFP-
RhoH-wt or GFP-RhoH-R1 (resistant to siRhoH-1) 48 h after siRNA transfection with siRhoH-1 or control siRNA. Cells were fixed 24 h after plasmid
transfection and stained for F-actin with Alexa Fluor 546 phalloidin and for DNA with DAPI. Scale bars 20 μm. b Left, cell area was measured using
ImageJ from F-actin-stained images. Scatter dot plots show mean +/− SEM; at least 84 cells/condition were analysed from three independent
experiments, n.s. not significant, ***p ≤ 0.001, by one-way analysis of variance (ANOVA). Right, representative immunoblot from cell lysates, probed
with the indicated antibodies. GAPDH was used as a loading control
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RhoH-depleted cells, which could inhibit cell rounding
during cytokinesis. For example, compounds such as
Rho kinase (ROCK) inhibitors both increase spread area
and inhibit cytokinesis [32, 33]. Consistent with an in-
hibition of cytokinesis, the total cell number was lower
96 h after RhoH siRNA transfection compared to con-
trol cells, but not at 48 or 72 h (Fig. 6h).
RhoH alters Rac activity distribution and membrane
protrusion
Since increased cell spread area and loss of cell polarity
are induced by active Rac1 in PC3 cells [20, 30], we
investigated whether RhoH affected Rac1 activity.
Indeed, RhoH has previously been reported to regulate
Rac activity in haematopoietic progenitor cells (HPCs)
[34]. However, RhoH depletion did not affect total Rac1
activity in PC3 cells, nor did it alter total Cdc42 or RhoA
activity (Fig. 8a, b). To investigate whether RhoH
affected where Rac1 is active in cells, we used a fluores-
cence resonance energy transfer (FRET)-based Rac1
activity FLARE biosensor [35, 36]. In control siRNA-
transfected cells, Rac1 activity was generally polarised
and localised to one or two discrete areas of the cell per-
iphery. In contrast, in RhoH-depleted cells, Rac1 activity
was more uniformly localised around the cell periphery
(Fig. 8c; Additional file 5: Movie S4, Additional file 6:
Movie S5 and Additional file 7: Movie S6).
Automated line scan analysis was carried out to quan-
tify Rac1 biosensor activity at the edge of cells [37]. Rac1
activity was highest close to the cell edge in PC3 cells, as
previously reported in mouse embryonic fibroblasts [35]
(Fig. 8d). Rac1 activity was correlated with protrusion
and retraction rate of the plasma membrane. In control
PC3 cells, Rac1 was active in protruding and retracting
regions of cells (Fig. 8d, e). By contrast, in RhoH-
depleted cells, Rac1 was also active in regions of the
membrane that were neither protruding nor retracting
(Fig. 8e). These results indicate that RhoH functions to
enhance Rac1 coupling to membrane protrusion,
explaining why RhoH-depleted cells are impaired in cell
migration. Although Rac1 is active in these cells, its
activity does not correlate with membrane protrusion.
RhoH co-localises with and associates with Rac1 and PAK2
Given that RhoH alters the localisation of active Rac1,
we investigated whether RhoH co-localises with Rac1.
We observed that RhoH localised in discrete dots in the
cytoplasm (which could be membrane vesicles) and at
the edges of lamellipodia (Fig. 9a). RhoH expression
promoted cell elongation and cell polarity (Fig. 9b, c),
consistent with a role in regulating Rac1 activity. When
co-expressed with Rac1, RhoH co-localised with Rac1 in
lamellipodia and membrane ruffles, as well as to
vesicular structures (Fig. 9a). RhoH also co-
immunoprecipitated with Rac1, indicating that they
associate in cells (Fig. 9d).
Of the Rho GTPase effectors that were hits in our
siRNA screen (Table 1), PAK2 and PAK5 (named PAK7
in the screen) are potential RhoH as well as Rac1 inter-
actors. PAK1 and PAK5 have previously been reported
to interact with RhoH [38, 39]. All of the PAK proteins
we tested (PAK1, PAK2, PAK4, PAK5 and PAK6) co-
immunoprecipitated with GFP-RhoH (Fig. 10a), but GFP
alone did not pull down either PAK1 or PAK2 (data not
shown), indicating that the interaction is specific. PAK2
is more highly expressed than PAK1 in PC3 cells [40],
which may explain why PAK2 but not PAK1 was a hit in
our screen. Both PAK2 and Rac1 were detected in RhoH
immunoprecipitates (Fig. 10b), indicating that Rac1,
PAK2 and RhoH might form a ternary complex.
Like RhoH depletion, PAK2 depletion reduced migra-
tion in the modified scratch wound assay (Fig. 10c) and
increased cell spread area (Fig. 10d, e). Our previous
studies showed that PAK2 depletion reduced HGF-
induced PC3 cell migration [40]. PAK2 depletion with
two independent siRNAs also reduced migration speed
and distance migrated in the absence of HGF
stimulation (Fig. 10f ). PAK2 depletion reduced GFP-
RhoH-induced PC3 cell elongation, indicating that PAK2
mediates morphological responses to RhoH (Fig. 9b, c).
However, RhoH did not affect the level of phosphory-
lated PAK, using an antibody that is a readout for PAK
activity, because it detects auto-phosphorylated PAK1
(residues 199/204), PAK2 (residues 192/197) and
probably PAK3 (Fig. 10g).
We then investigated whether RhoH altered PAK2
localisation (Fig. 11). PAK2 overexpression in PC3 cells
induced multiple lamellipodial protrusions, and PAK2
localisation was enriched in these protrusions (as previ-
ously described for PAK1 in Swiss 3T3 cells [41]). RhoH
depletion altered PAK2 localisation and reduced PAK2-
induced lamellipodia (Fig. 11, see arrows).
Together our data indicate that RhoH associates with
both Rac1 and PAK2 to promote cell migratory polarity.
Discussion
The RNAi screen we report here has identified multiple
regulators of cell migration in prostate cancer cells,
including Rho GTPases, RhoGEFs, RhoGAPs and effec-
tors. siRNA pools targeting closely related RhoGEFs,
RhoGAPs and effectors give opposite phenotypes, indi-
cating that they are not functionally redundant but have
distinct roles in cell signalling. Unexpectedly, RhoH was
a hit in the screen that reduced cell migration when it
was depleted. Our observations show that RhoH-
depleted cells lose migratory polarity and that this corre-
lates with de-localised Rac1 activation around the cell
periphery. We show that RhoH associates with both
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Rac1 and the Rac1 target PAK2, and co-localises with
Rac1 in lamellipodia. In addition, PAK2 contributes to
the effects of RhoH on cell shape and migratory polarity,
indicating that RhoH acts together with Rac1 and PAK2
to stimulate cell migration.
Previous expression analysis implied that RhoH is
expressed only in haematopoietic cells, and thus it was
surprising that it had a phenotype in a prostate cancer
cell line. RhoH function has been investigated primarily
in T cells and HPCs [19]. Whereas RhoH is required for
optimal migration of PC3 cells, it appears to suppress
migration of HPCs. For example, mouse HPCs from
rhoH-null mice have increased migration and
chemotaxis, which correlates with increased Rac1
a
c
d
b
e
Fig. 8 RhoH alters the distribution of active Rac1. a RhoH does not affect total Rac1 activity. PC3 cells transfected with the indicated siRNAs were
analysed for Rac1 activity using GST-PBD and pulldown assays. Blot is representative of three independent experiments. The ratio of GTP-Rac1/
Total Rac1 (compared to siControl) is indicated under the blot panels. b RhoH does not affect RhoA or Cdc42 activity. PC3 cells transfected with
the indicated siRNAs were analysed for Cdc42 (top) or RhoA (bottom) activity using GST-RBD or GST-PBD beads and pulldown assays. Blot is
representative of three independent experiments. Graph shows the ratio of GTP-RhoA/Total RhoA or GTP-Cdc42/Total Cdc42 (compared to
siControl); n = 3, ns non-significant, **p ≤ 0.01, Student’s t test. c–e RhoH affects Rac1 activity distribution. 24 h after transfection with the
indicated siRNAs, cells were transfected with DNA encoding a Rac1 biosensor including YPet PAK1-PBD and CyPet Rac1. Cells were imaged 24 h
later by time-lapse microscopy on a wide-field microscope by epifluorescence. c Two example images of Rac1 activity distribution are shown for
each siRNA. Scale bars 20 μm. d Graph of line scans (12 cells × 60 frames per cell) showing Rac1 activity with respect to distance from the edge
of the cell and also depending on whether the cell edge was protruding or retracting. e Rac1 activity as a function of distance from cell edge
and speed of membrane protrusion or retraction, n = 12 cells per condition
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activity [33, 42]. The contribution of RhoH to T cell mi-
gration appears to depend on both the concentration of
chemokine and the presence of T cell receptor signalling,
which also involves RhoH [11, 38, 43, 44] and Rac [19].
RhoH overexpression inhibits chemotaxis of T cells, and
RhoH depletion increases their migration speed in vitro
and homing to lymph nodes in vivo [43]. However, at
high levels of the chemokine CXCL12, Jurkat T cell mi-
gration depends on RhoH, whereas at low levels of
CXCL12 it suppresses cell migration [38]. Thus, under
certain conditions, RhoH is a positive regulator of T cell
migration, similar to our observations in prostate cancer
cells. It is also possible that constitutive loss of RhoH in
cells derived from rhoH-null mice selects for cells with
higher Rac1 activity, to compensate for the effects of
RhoH loss in reducing Rac1-induced protrusion. By con-
trast, under our conditions of acute RhoH depletion, the
cells do not have time to adjust their signalling networks
to Rac1, and hence have reduced migration speed.
RhoH has previously been reported to interact with
PAK1 and PAK5 [38, 39], but the phenotypic conse-
quence of this interaction has not been determined.
Here, we show that RhoH associates with both Rac1 and
PAK2, and acts through PAK2 to regulate migratory
polarity in PC3 cells. Although RhoH affects the distri-
bution of active Rac1 and co-localises with Rac1 in
lamellipodia, Rac1 itself is not a hit in our migration
assay (Table 1), possibly because Rac2 is also expressed
in PC3 cells. Indeed, Rac2 can induce lamellipodia simi-
lar to Rac1 [45]. Surprisingly, Rac3 depletion increased
migration. Rac1 and Rac3 have previously been reported
to have opposite effects on neuronal cell adhesion [46],
and only Rac1 and not Rac3 depletion reduced lamelli-
podia in glioblastoma cells [47]. It is thus probable that
Rac3 acts in a different way than Rac1 and Rac2 in regu-
lating cell migration.
Our analysis of prostate cancer gene expression data
suggests that higher RhoH expression correlates with
a d
b c
Fig. 9 RhoH co-localizes and interacts with Rac1. a RhoH partially co-localizes with Rac1. Cells were seeded on Matrigel-coated coverslips and
transfected with GFP-Rac1 and/or HA-RhoH as indicated. After 24 h cells were fixed and stained for F-actin with Alexa Fluor 633 phalloidin, for
anti-HA antibodies for HA-RhoH and for DNA with DAPI. Images were acquired by confocal microscopy. Scale bar 10 μm. b, c RhoH promotes cell
elongation, which is not affected by PAK2. 48 h after siRNA transfection with siPAK2-2/3 or control siRNA, cells were transfected with GFP or GFP-
RhoH. Cells were fixed and stained for F-actin with Alexa Fluor 546 phalloidin and DNA with DAPI. Cell elongation factor and shape factor were
measured using ImageJ from F-actin-stained images. Scatter dot plots show mean +/− SEM; cells were analysed from three independent
experiments, n.s. non-significant, *p ≤ 0.05, Student’s t test. d Rac1 and RhoH co-immunoprecipitate. COS7 cells were transfected with constructs
encoding GFP, HA-RhoH and/or GFP-Rac1 as indicated. After 24 h, lysates were immunoprecipitated with anti-GFP and analysed by western
blotting with the indicated antibodies
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Fig. 10 PAK2 mediates the effects of RhoH on cell shape. a, b RhoH co-immunoprecipitates with PAKs. COS7 cells were transfected with constructs
encoding GFP-RhoH and myc epitope-tagged PAKs (a) or HA-RhoH, GFP-Rac1, Myc-PAK2 or GFP alone (b). After 24 h, lysates were incubated with
GFP-Trap beads (GFP IP) followed by western blotting with the indicated antibodies. Results shown are representative of three independent
experiments. c PAK2 depletion reduces cell migration. PC3 cells were transfected with the indicated siRNAs and Oris™ migration assay carried out as in
Fig. 2. Migration is shown as a percentage of siControl +/− SEM, n = 3; *p ≤ 0.5, ***p ≤ 0.001, Student’s t test. Representative immunoblot from cell
lysates probed with the indicated antibodies. GAPDH was used as loading control. d–f PAK2 depletion increases cell area and decreases migration.
PC3 cells were transfected with the indicated siRNAs. d After 72 h, cells were fixed and stained for F-actin (Alexa Fluor 546 phalloidin) and DNA (DAPI).
Cell area was measured from F-actin-stained images. Scatter dot plots show mean +/− SEM; n = 3 (> 125 cells/condition), ***p ≤ 0.001, Student’s t test.
e Representative images used for d; scale bar 10 μm. f Cells were seeded 48 h after transfection in RPMI containing 0.1% FCS and monitored by time-
lapse microscopy for 24 h, images taken every 5 min. At least 50 cells were tracked from two independent experiments. Boxes of box and whisker plots
show median, 25th and 75th percentiles; whiskers show minimum and maximum values; *p ≤ 0.05, **p ≤ 0.01, Student’s t test. g RhoH does not alter
PAK activity. PC3 cells were transfected with the indicated siRNAs, cultured for 24 h in medium containing 0.1% FCS then stimulated with 20 ng/ml
HGF for 10 min. Cell lysates were probed with the indicated antibodies. Anti-phospho-PAK recognises PAK1, PAK2 and PAK3. GAPDH was used as
loading control. Graph shows densitometric quantification of western blots. n = 3; ns non-significant, Student’s t test
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more rapid cancer progression, and thus the role of
RhoH in prostate cancer warrants further investigation.
Interestingly, PAK2 was found to be more active in
castration-resistant prostate cancers compared to
castration-sensitive cancers and to contribute to prostate
cancer cell invasion as well as proliferation in vitro [48].
This implies that PAK2 could act with RhoH to promote
cancer progression.
Similar to RhoH depletion, knockdown of either RhoC
or the ezrin-radixin-moesin (ERM) protein radixin in
PC3 cells leads to an increase in spread area [20, 30]. In
both RhoH- and RhoC-depleted cells, Rac1 is uniformly
activated around the periphery rather than in discrete
areas in control cells. RhoC depletion also prevents cell
polarisation and strongly inhibits random migration [30]
as well as in the modified scratch wound assay (our data;
Table 1). However, RhoH-depleted cells have small and
persistent areas of active membrane protrusion and re-
traction around the periphery, whereas RhoC-depleted
cells tend to ruffle all around the periphery. Thus, they
are likely to affect cell spread area by different mecha-
nisms. In radixin-depleted PC3 cells, global Rac1 activity
is increased via Vav GEFs [20], whereas RhoH or RhoC
depletion does not affect global Rac1 activity.
During cell attachment to an extracellular matrix, cells
initially spread uniformly and then start to polarise and
migrate. During this initial phase, Rac1 is active
throughout the cell periphery, inducing Arp2/3
complex-mediated lamellipodial protrusion to drive
spreading [49]. We propose that RhoH-depleted cells
rarely switch from this uniform spreading mode to a
polarised migratory morphology, because they have a
reduced ability to turn off Rac1 around the periphery so
that it is localised to a specific area in order to form a
leading edge, which in turn involves PAKs. These highly
spread cells represent the population of RhoH-depleted
cells that migrate very little. Rac1 remains uniformly
active on the plasma membrane, and since the cells have
already spread, this active Rac1 is no longer able to drive
membrane protrusion at all places where it is active.
Instead, it would stimulate protrusion only in focal
regions around the periphery where the membrane has
stochastically retracted.
Our work implies that acquisition of RhoH expression
in epithelial cancers would promote cell migration and
invasion by restricting Rac1 activity and hence protru-
sion to one area of the plasma membrane. This would
increase the persistence of cancer cell migration through
tissues and ultimately contribute to cancer progression
and metastasis.
Methods
Cell culture and transfection
PC3, LNCaP, T47D and DU145 cells were cultured in
RPMI-1640 medium containing 10% FCS. MDA-MB-
231, MCF7, BT20, HT29, A376M2 and COS7 cells were
cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% FCS. MCF10A cells were cul-
tured in DMEM/F12 medium supplemented with 5%
horse serum, 20 μg/ml epidermal growth factor (EGF),
100 ng/ml cholera toxin, 100 μg/ml insulin and 0.5 μg/
ml hydrocortisone. SUM159 cells were cultured in F12
medium supplemented with 5% FCS, 5 μg/ml insulin
and 1 μg/ml hydrocortisone. All media were
supplemented with 100 U/ml penicillin and 50 μg/ml
streptomycin.
Fig. 11 RhoH depletion alters PAK2 localisation and PAK2-induced
lamellipodia. PC3 cells were transfected with the indicated siRNAs.
After 48 h, cells were transfected with empty vector or vector
encoding myc-PAK2. Cells were fixed 24 h later and stained for F-
actin with Alexa Fluor 546 phalloidin, anti-myc antibodies for Myc-
PAK2 and DNA (DAPI). Representative images of cells are shown.
Scale bar 10 μm. Arrows indicate protrusions with no PAK2 or in
which PAK2 does not overlap with F-actin
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PC3 cells were transfected with siRNAs using Oligofec-
tamine (Invitrogen) in Optimem without antibiotics. The
medium was changed to RPMI-1640 growth medium with
antibiotics 6 h after transfection. siRNAs were purchased
from Dharmacon or Sigma-Aldrich. Sequences of siRNAs
are shown in Additional file 1: Table S1. Plasmids were
transiently transfected into PC3 cells using Lipofectamine
2000 (Invitrogen).
Plasmid construction and mutagenesis
The human astrocyte (HA)-epitope-tagged RhoH gene
in pRC/CMV was a kind gift from Jeffrey Settleman
(Massachusetts General Hospital, Boston, MA, USA).
HA-RhoH was mutated to make it resistant to siRhoH-1
(GFP-RhoH-R1) by site-directed mutagenesis, using a
QuikChange mutagenesis kit (Stratagene). The nucleo-
tide change was verified by DNA sequencing (Eurofins-
MWG, UK). Wild-type RhoH and RhoH-R1 were
subcloned into pEGFP-N.
RNA isolation, PCR and qPCR
RNA was isolated from cells using RNeasy Mini Kits (Qia-
gen). Contaminating DNA was used with a DNase-free kit
(Ambion). For complementary DNA (cDNA) synthesis, a
SuperScript VILO Kit was used (Invitrogen). qPCR was
carried out with cDNA using SYBR Green-containing
Master Mix (Primer Design). GADPH was used as a refer-
ence gene. The qPCR oligonucleotide primers used for
RhoH were as follows: F, GAGAAGTAACATTCTGC
AAATCGC R, AGCACACGCCATTCAGCAAG; for
Rac2: F, GCAAGACCTGCCTTCTCATCA R, GCTGT
CCACCATCACATTGG; for RhoA: F, CAACTATGATT
ATTAACGATGTCCAACC R, TGGTGTGTCAGGTGG-
GAGTG; and for GAPDH: F, GTGAAGGTCGGAGTC
AACG R, TGAGGTCAATGAAGGGGTC.
Migration assay and screen conditions
PC3 cells were incubated with 2 μM CFSE (Molecular
Probes) for 20 min in phosphate-buffered saline (PBS)
followed by incubation in medium for 15 min, then
washed to remove excess dye. Cells (8 × 104/well) were
transfected in suspension, in 96-well dishes containing
50 nM siRNA pools or 100 nM single siRNAs, with
Lipofectamine 2000 in 150 μl of Optimem for 16 h.
After siRNA transfection, 3 × 104 cells from each trans-
fection well were seeded around Oris inserts in each of
two wells on 96-well plates, in medium containing 1%
FCS. Where indicated, wells were pre-coated with Matri-
gel (100 μg/ml; BD Biosciences). The inserts were
removed 48 h after siRNA transfection, and fluorescence
images were acquired for each well (t = 0 h), using a
TE2000 Nikon inverted microscope with a motorised
stage (Prior) and 4× objective. HGF (20 ng/ml, Pepro-
Tech, Rocky Hill, NJ, USA) was added to one of the two
wells for each siRNA transfection. After 24 h, a second
fluorescence image was acquired from the same position.
The fluorescence images were thresholded to select only
the cells, and the migration area was determined as the
area free of cells at 0 h. The migration index was calcu-
lated as the percentage of the migration area covered
with cells (fluorescent pixels) 24 h after removing the
stoppers. The mean and standard deviation (SD) of three
independent experiments were calculated for each
siRNA. A Z-score was allocated to each siRNA, where
the Z-score is the difference between the mean migra-
tion index for an siRNA and the mean for all the siRNAs
in the plate divided by the SD of all the siRNAs in the
plate. A Z-score of 1.0 was selected to classify the differ-
ent siRNAs into three categories: impaired migration
(those siRNAs with Z-score < −1.0), accelerated migra-
tion (those siRNAs with Z-score > 1.0) or HGF-
dependent (if the Z-score was > −1.0 in normal medium
but < −1.0 in medium supplemented with HGF).
To test for the effects of siRNAs on cell viability,
CFSE-stained cells (2 × 104) transfected with siRNA
pools were seeded per well in 96-well plates. Fluores-
cence was measured on a Fusion α-FP Plate Reader
(Perkin Elmer) at 48 and 72 h after transfection. A via-
bility index corresponding to the 72 h/48 h fluorescence
ratio was calculated for each siRNA. Z-scores for the
viability of the cells were allocated to each siRNA, where
the Z-score is the difference between the mean viability
index for an siRNA and the mean for all the siRNAs in
the plate divided by the SD of all the siRNAs in the
plate. A Z-score of 1.0 was selected to classify the differ-
ent siRNAs into low viability (Z-score < −1.0) and good
viability (Z-score > 1.0).
Time-lapse microscopy and random migration analysis
For random migration, PC3 cells were seeded on a 6-
well or a 24-well plate 24 h after siRNA transfection,
and 24 h later images were acquired at 37 °C every 8
min for 24 h (Fig. 5a, b) or every 4 min for 24 h (Fig. 5c)
on a Nikon TE2000 microscope with a Prior stage and a
Hamamatsu ORCA camera controlled by MetaMorph
software (Molecular Devices, San Jose, CA, USA), using
a 10×/0.3 Plan Fluor objective. Cells were imaged in
medium containing 1% FCS (Fig. 5a, b) or in 0.1% FCS
with or without 20 ng/ml HGF (Fig. 5c). More than 50
cells per siRNA condition (Fig. 5a, b) or 100 cells per
condition (Fig. 5c) from three different experiments were
tracked using ImageJ software. Still images are from 72
h after transfection.
The cell tracks were analysed by pooling all the data
from all cells for each condition (siControl, siRhoH-1,
siRhoH-2; Fig. 5a, b). From these data the distribution of
the distance travelled in the x-direction between image
frames was calculated (Fig. 5d). These numbers were
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compared to predictions from a mathematical model of
cell migration. This model is a random walk in two di-
mensions, with memory of orientation from the prior
step. The model is defined by the following parameters:
mean speed, variance in speed and variance in cell orien-
tation. Initially the model could not satisfactorily capture
the data. We found that hypothesizing the existence of
two ‘states’ of migration improved the model fit such
that data were adequately described. Each migration
state has three parameters: mean speed, variance in
speed and variance in orientation. A fourth parameter, α,
is the fraction of time spent (mean across all cells) in the
first state. By fitting the model to the data, estimates for
each of these parameters were obtained.
Transwell migration assays
PC3 cells (8 × 104) were seeded 48 h after siRNA transfec-
tion per transwell (8-μm pore diameter, BD Biosciences)
in 0.1% FCS. The bottom well contained 1% FCS, a
chemoattractant. After 8 h, cells were fixed with 70% etha-
nol containing 0.2% crystal violet. Random images of cells
on the bottom of the transwell (10 per experimental con-
dition from each of three independent experiments) were
acquired using a Nikon Eclipse TS100 microscope with a
10× objective. Cells were counted using ImageJ (plugin
Cell Counter). For each experimental condition, the total
number of cells from the 10 images was divided by the
total number of cells for control siRNA-transfected cells.
Cell lysis, immunoprecipitation and western blotting
Cells were lysed 72 h after siRNA transfection in lysis
buffer A (50 mM Tris-HCl pH 8, 0.5 mM ethylenedi-
aminetetraacetic acid (EDTA), 150 mM NaCl, 1% NP-40
and protease and phosphatase inhibitor cocktails from
Roche). Lysates were homogenised through a needle or
sonicated, then centrifuged for 10 min at 16,000 g to
separate soluble from insoluble fractions.
For immunoprecipitations, cells were lysed 24 h
after plasmid transfection in lysis buffer B (20 mM
Tris-HCl, pH 8, 130 mM NaCl, 1% Triton X-100, 1
mM dithiothreitol (DTT), 10 mM NaF, 1 mM phenyl-
methylsulfonyl fluoride, 10 μg/ml aprotinin, 10 μg/ml
leupeptin, 0.1 mM sodium orthovanadate), and the
centrifuged supernatants were incubated with GFP-
Trap beads (ChromaTek) or mouse anti-HA antibody
bound to agarose (Sigma-Aldrich) and rotated for 2 h
at 4 °C. The beads were washed extensively with lysis
buffer, and the bound proteins were analysed by so-
dium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) and immunoblotting. Bound
antibodies were visualised with horseradish
peroxidase-conjugated goat anti-immunoglobulin G
antibodies and enhanced chemiluminescence (ECL,
GE Healthcare).
The antibodies used for western blotting were GAPDH
(RRID:AB_2107445), phospho-PAK1/2 (S199/204 on
PAK1; S192/197 on PAK2; RRID:AB_2160222), PAK1
(RRID:AB_10827914), PAK2 (RRID:AB_228338), RhoH
(RRID: AB_1856269), GFP (RRID:AB_221569), Cdc42
(RRID:AB_2078085), Rac1 (RRID:AB_309712), RhoA
(RRID:AB_10693922), α-tubulin (RRID:AB_477593), HA
(RRID:AB_10094468 RRID:AB_2314672), myc epitope
(RRID:AB_439680), ERK1 (RRID:AB_2140110) or phos-
pho ERK1/2 (RRID:AB_331646). HRP-labelled goat anti-
mouse, anti-rat and anti-rabbit antibodies were also used
(GE Healthcare).
GTPase activity assays
GST-PBD (p21-binding domain of PAK) for Rac1 and
Cdc42 activity assays or GST-RBD (Rho-binding domain
of Rhotekin) for RhoA activity assays was produced by
lysing bacterial pellets in cold STE buffer (10 mM Tris
pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM phenyl-
methylsulfonyl fluoride). Lysates were homogenised
using a 19-gauge needle, then lysozyme (100 μg/ml) was
added and incubated for 15 min on ice. DTT (5 mM)
was added followed by Tween-20 (1%) and SDS (0.03%).
The homogenate was centrifuged at 13,000 g at 4 °C for
30 min. The supernatant was transferred to a fresh tube
containing glutathione-conjugated sepharose beads and
rotated for 2 h at 4 °C. The beads were washed in STE
buffer followed by Mg2+ lysis buffer (25 mM Hepes, pH
7.5, 150 mM NaCl, 1% NP-40, 10 mM MgCl2, 1 mM
EDTA, 25 mM NaF, 1 mM Na3VO4, 1 mM phenyl-
methylsulfonyl fluoride, 10% glycerol and two cocktail
protease inhibitor tablets (Roche)).
PC3 cells were transfected with 100 nM siRhoH-1,
siRhoH-2 or control siRNA. After 72 h, the cells were
washed twice with ice-cold PBS and lysed in ice-cold
Mg2+ lysis buffer. Cell lysates were centrifuged for 5 min
at 13,000 g at 4 °C, and 40 μl of supernatant was re-
moved to determine total Rac1, Cdc42 or RhoA levels.
The remaining supernatants were incubated with GST-
PBD or GST-RBD on glutathione-sepharose beads and
rotated at 4 °C for 2 h. The beads were washed exten-
sively in lysis buffer, and the bound proteins were sepa-
rated by SDS-PAGE and immunoblotted with anti-Rac1
(RRID:AB_309712), anti-Cdc42 (RRID:AB_2078085) or
anti-RhoA (RRID:AB_10693922) antibodies respectively.
Blots were quantified using ImageJ.
Cell staining, confocal microscopy and cell shape analysis
PC3 cells on Matrigel-coated glass coverslips were fixed
with 4% paraformaldehyde solution in PBS for 20 min,
permeabilised with 0.1% Triton X-100 in PBS for 5 min
and blocked with 5% bovine serum albumin (BSA) in PBS
for a further 30 min. Cells were incubated for 1 h with
Alexa Fluor 546-conjugated phalloidin (Molecular Probes)
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to stain actin filaments (F-actin) and fluorescein isothio-
cyanate (FITC)-labelled mouse α-tubulin antibody (RRI-
D:AB_476967), anti-HA antibody (RRID:AB_10094468 or
RRID:AB_2314672), anti-myc epitope antibody (RRI-
D:AB_439680) or anti-GFP antibody (RRID:AB_221569)
and 4′,6-diamidino-2-phenylindole (DAPI) to stain nuclei.
When necessary, bound antibodies were visualised with
anti-rabbit and anti-rat Alexa Fluor 546/488 conjugated
antibodies. Coverslips were mounted on slides in fluores-
cence mounting medium (Dako), and images were gener-
ated with a Zeiss LSM Zen 510 confocal microscope using
a 40×/1.3 NA objective and Zen software.
For cell shape analysis, cells stained for F-actin with
phalloidin were analysed. ImageJ was used to calculate
cell spread area, elongation and roundness (shape
factor). Shape descriptors were calculated using ImageJ
or MetaMorph software and are defined as follows:
Circularity = [Area]/[Perimeter], with a value of 1.0 indi-
cating a perfect circle; as the value approaches 0.0, it
indicates an increasingly elongated shape. Shape factor =
4πA/P2; a value near 0 indicates a flattened object,
whereas a value of 1.0 indicates a perfect circle. Elong-
ation factor = 1/Shape factor.
Cell number analysis
PC3 cells (6–8 × 104) were plated on 6-well tissue
culture dishes that were pre-coated for 1 h with 100 μg/
ml Matrigel (BD Biosciences). After 16 to 24 h, the cells
were transfected with 100 nM siRNAs. Cells were
counted at 48 h, 72 h or 96 h after transfection using a
haemocytometer.
Rac1 activity analysis by FRET
PC3 cells plated on Matrigel-coated coverslips were
transfected with 100 nM siRNAs, followed by transfec-
tion with a FLARE biosensor for Rac1, 48 and 24 h
before imaging respectively. The FLARE biosensor was a
modification of that previously described [35]. It con-
sisted of a PAK1 PBD domain fused to YPet followed by
CyPet-Rac1, on one open reading frame. A 2(P)A ‘self-
cleaving’ sequence from FMDV was inserted, leading to
cleavage of PBD-YPet from CyPet-Rac1 during transla-
tion [50]. For imaging, phenol red-free RPMI-1640
medium supplemented with 1% FCS was used. Cells
were imaged in a chamber heated to 37 °C using an
Olympus IX81 inverted microscope with a 40×/1.3 NA
objective fitted with an objective heater (Bioptechs).
Cyan fluorescent protein (CFP) and FRET images were
acquired simultaneously every 10 s for 10 min through
two CoolSNAP HQ2 CCD cameras (Photometrics) using
a TuCam camera adapter (Andor Technology). Image
processing and FRET analysis were carried out as previ-
ously described [51].
Line scan analysis and correlation with cell edge
protrusion/retraction speed analysis
Line scan analysis was performed on FRET images of 12
cells from three independent experiments. FRET inten-
sity of line scans over 60 frames per cell acquired every
10 s was analysed as described [37] and plotted as a
function of distance from the cell edge. The correlation
between the protrusion and retraction speed at the cell
edge and the FRET signal was also calculated [37].
Analysis of RhoH expression in prostate cancers
The MSKCC prostate cancer mRNA expression dataset
and descriptive statistics of associated clinical data were
obtained from the cBio Cancer Genomics Portal [52].
RhoH mRNA expression of samples were divided into ter-
ciles, with the top tercile designated as high-RhoH and the
rest of the dataset as low-RhoH. The data were fitted to a
Cox proportional hazards regression model to estimate
RFS with RFS defined as time until PSA levels increased
to ≥ 0.2 ng/ml [31]. The Wald test was used to assess
significance. Statistical analyses were performed using the
statistical environment R (http://www.r-project.org/).
Statistical analysis
All data are presented as mean plus SEM. The statistical
analysis was performed using GraphPad Prism software.
The statistical significance analysis was calculated using
an unpaired two-tailed t test (for comparing two condi-
tions) or by one-way analysis of variance (ANOVA) with
multiple conditions, or a Wald test (for survival analysis).
Conclusions
Using an RNAi screen, we show that multiple Rho
GTPases and their interacting partners, including GEFs,
GAPs and effectors, regulate cell migration in PC3 pros-
tate cancer cells. One of the screen hits is RhoH, which
was assumed to be expressed only in haematopoietic
cells, but we show is expressed in a panel of epithelial
cancer cell lines. RhoH promotes cell migration and
chemotaxis of PC3 cells. RhoH co-localises with and as-
sociates with Rac1 and PAK2, a Rac1 effector and a hit
in our RNAi screen, and promotes coupling of Rac1 ac-
tivity to membrane protrusion events as well as PAK2
localisation to lamellipodia. We propose that RhoH
stimulates Rac1- and PAK2-driven membrane protrusion
and hence enhances cell migration.
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Additional file 5: Movie S4. Rac1 biosensor in PC3 cells transfected
with siControl. One frame every 10 s. Scale bar 10 μm. (MP4 1231 kb)
Additional file 6: Movie S5. Rac1 biosensor in PC3 cells transfected
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